Greenwich LifeSciences (GLSI)

• Market cap: $114M
• 1 day: -1.56%
• 5 days: 0.99%
• 1 month: -20.39%
• 3 months: -30.39%
• 6 months: -15.38%
• Year to date: -30.15%
• 1 year: -38.58%
• 5 years: 135.63%
• 10 years: 64%
• Sector: Healthcare
• Industry: Biotechnology

About: Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Employees: 8